Epidemiology

Longhorn Vaccines and Diagnostics to Present Data on LHNVD-105, a Universal Vaccine Candidate, at ECCMID 2024

Retrieved on: 
Thursday, April 11, 2024
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Neuraminidase, Infection, Public, University, Gram-positive bacteria, Mycobacterium tuberculosis, Epidemiology, Abstract, ECCMID, Epitope, Vaccine

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.
  • ECCMID will take place online and in-person in Barcelona, Spain, from April 27-30, 2024.
  • The first two abstracts will detail data on LHNVD-105, an adjuvanted composite peptide universal influenza vaccine, and the monoclonal antibodies it produces.
  • Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)
    Session Title: 10f.

Global Oxygen Cylinders and Concentrators Market Analysis and Forecasts, 2020-2024 and 2025-2030: Internet of Things (IoT) Connectivity Transforms Oxygen Concentrators into Smart Healthcare Devices - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 11, 2024
Health, Medical Supplies, Medical Devices, USD, Epidemiology, Internet of things, Porter's five forces analysis, Miniaturization, Investment, Chronic obstructive pulmonary disease, SWOT, Skin, Death, Health care, Vital signs, Patient safety, Mask, Incidence, Sleep apnea, Patient, Asthma, Prevalence, IHME, Medication, COPD, Medical device

The Global Oxygen Cylinders and Concentrators market showcased growth at a CAGR of 5.87% during 2020-2023.

Key Points: 
  • The Global Oxygen Cylinders and Concentrators market showcased growth at a CAGR of 5.87% during 2020-2023.
  • The Oxygen Cylinders and Concentrators Market is expected to continue growing as the global population ages and the prevalence of respiratory diseases increases, driving the need for effective oxygen therapy solutions.
  • As the global population ages and environmental factors contribute to respiratory health issues, the need for oxygen cylinders and concentrators continues to grow.
  • Technological advancements in portable oxygen cylinders and concentrators have transformed respiratory care, offering greater convenience, mobility, and usability for patients.

NYU Langone's Perlmutter Cancer Center Earns Redesignation as a Comprehensive Cancer Center from the National Cancer Institute

Retrieved on: 
Thursday, April 18, 2024
Cancer, Chemoradiotherapy, Lung cancer, Woman, Certification, Epidemiology, Immunotherapy, FACT, NYU Langone Health, Doctor of Philosophy, National Cancer Institute, Research, NYU, Melanoma, Radiation therapy, CCSG, Patient, Faculty, Accreditation, Diagnosis, Messenger, Blood, Alec

NEW YORK, April 18, 2024 /PRNewswire/ -- NYU Langone Health's Laura and Isaac Perlmutter Cancer Center has once again been designated as a Comprehensive Cancer Center, the highest ranking awarded by the National Cancer Institute and further validation that it provides state-of-the-art, research-based approaches to preventing, detecting, and treating cancer.

Key Points: 
  • NEW YORK, April 18, 2024 /PRNewswire/ -- NYU Langone Health's Laura and Isaac Perlmutter Cancer Center has once again been designated as a Comprehensive Cancer Center, the highest ranking awarded by the National Cancer Institute and further validation that it provides state-of-the-art, research-based approaches to preventing, detecting, and treating cancer.
  • Perlmutter Cancer Center is among only 56 institutions recognized across the nation for earning this elite distinction.
  • Perlmutter Cancer Center achieved its ranking by demonstrating success in the following areas:
    Developing and offering the most advanced therapies and innovative clinical trials.
  • Experts at Perlmutter Cancer Center have also implemented screening approaches to diagnose lung cancer in non-smokers.

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Financial management, Patient, Ageing, ...Continued, OI, Epidemiology, EMA, Pediatrics, Osteogenesis imperfecta, FDA, Lithium

LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2023, and provided an update on recent corporate highlights.

Key Points: 
  • “We reached a number of important milestones in 2023, which have set the stage for a potentially transformative 2024,” said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo.
  • Cosmic was initiated in the second half of 2023 and is anticipated to be fully enrolled in the first half of 2024.
  • Accordingly, the full year 2023 financial results are presented in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and in U.S. dollars.
  • Total ADS equivalents as of December 31, 2023 were 140,243,417, with each ADS representing five ordinary shares of the Company.

QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system

Retrieved on: 
Monday, March 25, 2024
PCR, Comment, Patient, Software, Epidemiology, RAM, Senior, QIAGEN, QGEN, Medical device

The upgraded diagnostic system, powered by the new QIAstat-Dx Operational Module PRO with a 64‑bit processor and 4GB of RAM, introduces the Remote Results Application, still unique in the syndromic testing space.

Key Points: 
  • The upgraded diagnostic system, powered by the new QIAstat-Dx Operational Module PRO with a 64‑bit processor and 4GB of RAM, introduces the Remote Results Application, still unique in the syndromic testing space.
  • The new feature, accessible through the QIAsphere cloud and exclusively available with QIAstat‑Dx Analyzer 2.0, allows users to view, comment and confirm diagnostic test results directly from their desktop and mobile devices in any location, facilitating seamless collaboration across the healthcare system.
  • This enables greater flexibility and collaboration between central and regional labs, especially in decentralized testing, reducing diagnostic processing time and ensuring patients receive accurate results more quickly.
  • Alternatively, the QIAstat-Dx Analyzer 2.0 enables in-house visibility of test results over a shared network.

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

Retrieved on: 
Monday, March 18, 2024
BCG, IGRA, Disease, Infection, Tuberculosis, World Tuberculosis Day, Incidence, Partnership, Molecular diagnostics, Interferon gamma release assay, CPD, Patient, Ageing, Epidemiology, Genetically modified bacteria, Senior, TST, IPPA, MPH, CDC, Vaccination, QIAGEN, Gold, WHO, TB, Physician, QGEN

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.

Key Points: 
  • Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.
  • A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
  • This collaboration follows the U.S. Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States.
  • Alexandra Ortega, MPH, MCHES, Executive Director of the IPPA, said, “Working together with QIAGEN allows us to educate panel physicians on the latest TB screening requirements, ensuring patients receive the most accurate and efficient testing available.

Pharming Group reports fourth quarter and full year 2023 financial results

Retrieved on: 
Thursday, March 14, 2024
Patient, Health care, Epidemiology, Executive Committee, Laboratory, Microsoft Access, Lymphocyte, Clinical trial, European Commission, APDS, MHLW, AEG, Welfare, Ageing, Committee, EMA, Trial of the century, PID, CTLA4, Safety, Pharmacokinetics, Ministry, CHMP, ODD, U.S. FDA, Prevalence, PTEN, Disease, HAE, Immunodeficiency, VUS, Literature, PIK3R1, PMDA, FDA, DSM-IV codes, Diagnosis, Civil service commission, IRP, Haploinsufficiency, Genetic testing, MAA, Autoimmunity, World Games, Iberian languages, Marketing, MHRA, Euronext Amsterdam, PIK3CD, Physician, Pharmaceutical industry

The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.

Key Points: 
  • The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.
  • Revenues increased to US$7.9 million in the fourth quarter of 2023, driven by the continued increase in patients on paid therapy, and revenues were US$18.2 million for 2023.
  • Pharming made continued progress in the fourth quarter of 2023 on leniolisib regulatory filings for APDS patients 12 years of age and older in key global markets.
  • Pharming filed regulatory submissions in Canada and Australia in the third quarter of 2023, and Israel in the second quarter.

Global Orthodontic and Orthopedic Market Report 2024 Featuring Leading Industry Players - Henry Schein, Align Technology, Institut Straumann A, American Orthodontics, and Envista - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Health, Surgery, Dental, Medical Devices, Splints, Prevalence, Environment, Incidence, Henry Schein, Trauma, Sale, Epidemiology, Align Technology, Orthodontics, GCC, Geography, Thermal expansion, USD, Lip, Genetic disorder, Brace, Dentistry

The "Global Orthodontic and Orthopedic Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Orthodontic and Orthopedic Market" report has been added to ResearchAndMarkets.com's offering.
  • The report will provide details about the orthodontic devices used in the treatment of dental disease and facial dental surgery.
  • This includes devices used for aligning teeth, due to damage caused by trauma or genetic disorder, or any aesthetic purpose.
  • The report includes market projections for 2028 and market shares for key players.

MindMed to Present at Upcoming April Medical Conferences

Retrieved on: 
Tuesday, April 2, 2024
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Medicine, COVID, MindMed, Epidemiology

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:

Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Carcinoma, Alkermes, Erasmus University Rotterdam, Cetuximab, Patient, SVP, ImClone Systems, Biostatistics, Merck, Epidemiology, Management, University, MBA, Merck Group, Limited partnership, MPH, Therapy, International school, PPD, Eli Lilly and Company, Marketing, Avelumab, Daiichi Sankyo

“We are very pleased to welcome Jeltje and Rita to our talented team.

Key Points: 
  • “We are very pleased to welcome Jeltje and Rita to our talented team.
  • Dr. Schulten received her medical degree from Erasmus University, Rotterdam, Netherlands and her MBA from the International School of Management RSM, Rotterdam, Netherlands.
  • Dr. Rita Dalal is a trained physician with extensive and diverse clinical research experience including in solid tumor oncology.
  • Previously, Dr. Dalal held clinical research scientist positions with Merck Sharp & Dohme Corp. and Eli Lilly and Company.